Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Moving forward, GenFleet will determine the next steps regarding the trial’s continuation around lymphoma as SELLAS’ focus remains in AML and spliceosome – chromatin mutations, including ASXL1 ...

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Thursday announced promising early data from its Phase 2a trial of SLS009 or tambiciclib ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, SLS009, in treating relapsed/refractory diffuse large B ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone;83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients- ...